These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10421772)

  • 1. Species, interindividual, and tissue specificity in endocrine signaling.
    Walker C; Ahmed SA; Brown T; Ho SM; Hodges L; Lucier G; Russo J; Weigel N; Weise T; Vandenbergh J
    Environ Health Perspect; 1999 Aug; 107 Suppl 4(Suppl 4):619-24. PubMed ID: 10421772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative mechanistically based dose-response modeling with endocrine-active compounds.
    Andersen ME; Conolly RB; Faustman EM; Kavlock RJ; Portier CJ; Sheehan DM; Wier PJ; Ziese L
    Environ Health Perspect; 1999 Aug; 107 Suppl 4(Suppl 4):631-8. PubMed ID: 10421774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of potential endocrine-related health effects at low-dose levels of exposure to PCBs.
    Brouwer A; Longnecker MP; Birnbaum LS; Cogliano J; Kostyniak P; Moore J; Schantz S; Winneke G
    Environ Health Perspect; 1999 Aug; 107 Suppl 4(Suppl 4):639-49. PubMed ID: 10421775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An approach to the development of quantitative models to assess the effects of exposure to environmentally relevant levels of endocrine disruptors on homeostasis in adults.
    Ben-Jonathan N; Cooper RL; Foster P; Hughes CL; Hoyer PB; Klotz D; Kohn M; Lamb DJ; Stancel GM
    Environ Health Perspect; 1999 Aug; 107 Suppl 4(Suppl 4):605-11. PubMed ID: 10421770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity.
    Welshons WV; Thayer KA; Judy BM; Taylor JA; Curran EM; vom Saal FS
    Environ Health Perspect; 2003 Jun; 111(8):994-1006. PubMed ID: 12826473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ignoring estrogenic mixtures underestimates risk.
    Erickson BE
    Environ Sci Technol; 2002 May; 36(9):179A-180A. PubMed ID: 12026960
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular circuits, biological switches, and nonlinear dose-response relationships.
    Andersen ME; Yang RS; French CT; Chubb LS; Dennison JE
    Environ Health Perspect; 2002 Dec; 110 Suppl 6(Suppl 6):971-8. PubMed ID: 12634127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of high production volume chemicals for estrogen receptor binding activity (II) by the MultiCASE expert system.
    Klopman G; Chakravarti SK
    Chemosphere; 2003 May; 51(6):461-8. PubMed ID: 12615097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selected aspects of xenoestrogens'mode of action taken from a group of persistent organochlorine compounds ].
    Struciński P; Ludwicki JK; Góralczyk K; Czaja K
    Rocz Panstw Zakl Hig; 2000; 51(3):211-28. PubMed ID: 11138478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of environmental endocrine-active substances on public health.
    Koifman S; Paumgartten FJ
    Cad Saude Publica; 2002; 18(2):354-5. PubMed ID: 11923878
    [No Abstract]   [Full Text] [Related]  

  • 11. Endocrine active agents: implications of adverse and non-adverse changes.
    Foster PM; McIntyre BS
    Toxicol Pathol; 2002; 30(1):59-65. PubMed ID: 11892727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine disrupters: an emerging environmental health problem.
    Rubin CH; Niskar AS
    J Med Assoc Ga; 1999 Dec; 88(4):27-30. PubMed ID: 10666990
    [No Abstract]   [Full Text] [Related]  

  • 13. An integrated "4-phase" approach for setting endocrine disruption screening priorities--phase I and II predictions of estrogen receptor binding affinity.
    Shi L; Tong W; Fang H; Xie Q; Hong H; Perkins R; Wu J; Tu M; Blair RM; Branham WS; Waller C; Walker J; Sheehan DM
    SAR QSAR Environ Res; 2002 Mar; 13(1):69-88. PubMed ID: 12074393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vivo test for endocrine disruptors].
    Kanno J
    Nihon Rinsho; 2000 Dec; 58(12):2495-501. PubMed ID: 11187744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human exposure to endocrine-active chemicals: hazard assessment problems.
    Safe S; Connor K; Ramamoorthy K; Gaido K; Maness S
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):52-8. PubMed ID: 9339480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological regulation of receptor-hormone complex concentrations in relation to dose-response assessments for endocrine-active compounds.
    Andersen ME; Barton HA
    Toxicol Sci; 1999 Mar; 48(1):38-50. PubMed ID: 10330682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transcriptional control by nuclear steroid hormone receptors and endocrine disruptants].
    Kato S
    Nihon Rinsho; 2000 Dec; 58(12):2439-45. PubMed ID: 11187734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolutionary biology of plant defenses against herbivory and their predictive implications for endocrine disruptor susceptibility in vertebrates.
    Wynne-Edwards KE
    Environ Health Perspect; 2001 May; 109(5):443-8. PubMed ID: 11401754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Endocrine Disruptors on Brain Development and Behaviour. Proceedings of a conference. 15-20 September 2001, Sicily, Italy.
    Colborn T
    Environ Health Perspect; 2002 Jun; 110 Suppl 3(Suppl 3):335-449. PubMed ID: 12201292
    [No Abstract]   [Full Text] [Related]  

  • 20. New modes of action for endocrine-disrupting chemicals.
    Tabb MM; Blumberg B
    Mol Endocrinol; 2006 Mar; 20(3):475-82. PubMed ID: 16037129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.